HilleVax, Inc. (NASDAQ:HLVX – Get Free Report)’s share price gapped up prior to trading on Friday . The stock had previously closed at $12.85, but opened at $13.14. HilleVax shares last traded at $13.21, with a volume of 5,923 shares.
HilleVax Stock Performance
The business’s fifty day moving average price is $14.97 and its two-hundred day moving average price is $15.39. The company has a debt-to-equity ratio of 0.11, a quick ratio of 13.80 and a current ratio of 13.80. The stock has a market capitalization of $503.55 million, a P/E ratio of -5.22 and a beta of -0.04.
Institutional Trading of HilleVax
A number of large investors have recently made changes to their positions in HLVX. Carlyle Group Inc. bought a new stake in shares of HilleVax in the 1st quarter worth about $30,096,000. Braidwell LP bought a new stake in shares of HilleVax in the 4th quarter worth about $27,106,000. Price T Rowe Associates Inc. MD purchased a new position in shares of HilleVax during the 2nd quarter worth about $12,037,000. Franklin Resources Inc. boosted its stake in shares of HilleVax by 85.2% during the 4th quarter. Franklin Resources Inc. now owns 1,246,141 shares of the company’s stock worth $20,848,000 after purchasing an additional 573,110 shares during the period. Finally, Morgan Stanley boosted its stake in shares of HilleVax by 487.0% during the 4th quarter. Morgan Stanley now owns 605,313 shares of the company’s stock worth $10,127,000 after purchasing an additional 502,197 shares during the period. 92.32% of the stock is currently owned by institutional investors.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
- Five stocks we like better than HilleVax
- How to Invest in Biotech Stocks
- 2 Stocks to Get You Ready for the Holiday Season
- What Investors Need to Know to Beat the Market
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.
